Pier Francesso Ferrucci

18PUBLICATIONS
96CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jan 28, 2026
Effect of Immune Checkpoint Inhibitor Therapy on Biventricular and Biatrial Mechanics in Patients with Advanced Cancer: A Short-Term Follow-Up Study.

Andrea Sonaglioni, Emanuela Fossile, Nicoletta Tartaglia

|Jun 17, 2025
GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation.

Fiorenza Lotti, Marine Melixetian, Thalia Vlachou

|Jan 03, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Paolo A Ascierto, Milena Casula, Jenny Bulgarelli

|Jun 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.

Reinhard Dummer, Pippa Corrie, Ralf Gutzmer

|Sep 01, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.

Paolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci

|Sep 01, 2022
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.

Georgina V Long, Pier Francesco Ferrucci, Adnan Khattak

Pageof 3

Frequent Collaborators

7 joint publications

Paolo Antonio Ascierto

6 joint publications

Reinhard Dummer

5 joint publications

Piotr Rutkowski

5 joint publications

Georgina V Long